- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Company Chief Reports on Progress in Licensing Proprietary Technology for New Generation of Biomedical Products
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, has announced the availability of an audio interview given by Company CEO, Michael Weiner, to online investor information service WallSt.net.
In the interview, Mr. Weiner described the scope of Biophan’s expanding intellectual property portfolio in nanotechnology and other areas that are enabling the development of new biomedical products that can solve critical issues in healthcare. He discussed the Company’s product and technology development agreements with leading medical instrument makers such as Boston Scientific, and outlined Biophan’s strategy to drive substantial revenue growth through licensing of its proprietary solutions to makers of products for the healthcare and life sciences marketplace.
The ten-minute streaming audio interview can be accessed at www.WallSt.net. To listen, click on the BIPH ticker symbol on the left hand column of the page or enter the BIPH symbol in the Audio Search window. Registration to listen to the interview is free.
Among the specific market sectors areas Mr. Weiner discussed are Biophan’s leadership in development of proprietary solutions to allow implanted medical devices, such as pacemakers, to be used safely in Magnetic Resonance Imaging (MRI) environments. The Company has also solved a range of problems that have traditionally prevented other implanted medical devices from being clearly and effectively imaged under MRI.
In addition, Mr. Weiner elaborated on the value of Biophan’s planned acquisition of AMRIS, a leading German-based developer of MRI-safe and image-compatible technology solutions and biomedical devices. The planned acquisition will significantly expand Biophan’s existing international intellectual property portfolio, granting the Company exclusive license to fifteen issued and pending patents, covering imaging of devices such as stents and other vascular implants. Biophan currently holds a total of 104 U.S. patents, licenses, or applications.
WallSt.net, owned by Digital Wall Street, is an online open network financial community that provides a number of services and tools to investors, including financial and market news, reports, and conferences. It can be found at http://www.WallSt.net.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 104 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. For additional investor-specific information, please visit www.trilogy-capital.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
NIST physicists show ion pairs perform enhanced 'spooky action' March 30th, 2017